Merck's Keytruda Qlex Approved In Japan For Subcutaneous Administration

Merck & Co Inc's Keytruda Qlex (Pembrolizumab And Berahyaluronidase Alfa-pmph) has been approved in Japan for subcutaneous administration for all Keytruda (Pembrolizumab) indications approved in Japan.